A U.S.-based prospective, multi-center, non-interventional study of the role of comprehensive genomic profiling in the clinic.

e22183 Background: Comprehensive genomic profiling is increasingly incorporated in cancer treatment decision-making in an effort to identify druggable genomic events. FoundationOne (F1) is next-generation sequencing-based comprehensive genomic profile introduced clinically in 2012. Prior work has highlighted the ability of this approach to identify clinically relevant genomic alterations (CRGA), i.e.-changes associated with an approved agent or a mechanism-based clinical trial, in more than 80% of pts (Johnson et al. Oncologist, 2014). To describe clinician’s use of F1 in practice, we undertook an observational registry study. Methods: This is an ongoing study to characterize use of F1 in routine clinical practice. Planned duration is u003e 2 years with ~18 months for patient (pt) enrollment and u003e 1 year follow-up/pt. Pts for whom F1 was ordered, informed consent was obtained and a F1 report was issued were considered eligible for participation. Results: 496 pts from 26 sites (community 81% ) comprise the pre...